4 days Ago By ABMN Staff
DURECT Co. ( NASDAQ:DRRX – Free Report ) – Equities researchers at Northland Capmk dropped their FY2024 earnings estimates for shares of DURECT in a note issued to investors on Thursday, November 14th. Northland Capmk analyst C.
Byrnes now anticipates that the specialty pharmaceutical company will post earnings of ($0.68) per share for the year, down from their prior estimate of ($0.67).
The consensus estimate for DURECT’s current full-year earnings is ($0.64) per share. Other equities research analysts have also issued research reports about the stock.
HC Wainwright restated a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th. StockNews.com initiated coverage on DURECT in a research report on Tuesday.
They issued a “sell” rating for the company. DURECT Stock Performance Shares of DRRX stock opened at $0.98 on Monday.
The firm has a market cap of $30.42 million, a price-to-earnings ratio of -1.61 and a beta of 1.
13. DURECT has a 52 week low of $0.48 and a 52 week high of $1.
88. The firm’s 50-day simple moving average is $1.33 and its two-hundred day simple moving average is $1.
37. Hedge Funds Weigh In On DURECT Several large investors have recently modified their holdings of the business. International Assets Investment Management LLC grew its stake in DURECT by 41.
3% in the 2nd quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock valued at $28,000 after buying an additional 6,300 shares in the last quarter. Accredited Investors Inc.
purchased a new position in shares of DURECT in the second quarter valued at $113,000. Geode Capital Management LLC grew its position in shares of DURECT by 4.8% in the third quarter.
Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock valued at $429,000 after purchasing an additional 14,658 shares in the last quarter. Gagnon Securities LLC lifted its holdings in DURECT by 6.0% during the 1st quarter.
Gagnon Securities LLC now owns 380,131 shares of the specialty pharmaceutical company’s stock worth $460,000 after purchasing an additional 21,425 shares in the last quarter. Finally, Richmond Brothers Inc. boosted its stake in DURECT by 39.
5% in the 2nd quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock worth $1,383,000 after purchasing an additional 303,670 shares during the period.
Hedge funds and other institutional investors own 28.03% of the company’s stock. About DURECT ( Get Free Report ) DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program.
The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. Featured Articles Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter .
.
